These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37399930)

  • 1. Mesalazine hollow suppositories based on 3D printing for treatment of ulcerative colitis.
    Wei M; Liu D; Sun Y; Xie H; Du L; Jin Y
    Int J Pharm; 2023 Jul; 642():123196. PubMed ID: 37399930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of 3D printing technology for generating hollow-type suppository shells.
    Tagami T; Ito E; Hayashi N; Sakai N; Ozeki T
    Int J Pharm; 2020 Nov; 589():119825. PubMed ID: 32861769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
    Watanabe M; Nishino H; Sameshima Y; Ota A; Nakamura S; Hibi T
    Aliment Pharmacol Ther; 2013 Aug; 38(3):264-73. PubMed ID: 23734840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D printing of unique water-soluble polymer-based suppository shell for controlled drug release.
    Tagami T; Hayashi N; Sakai N; Ozeki T
    Int J Pharm; 2019 Sep; 568():118494. PubMed ID: 31276763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
    Kato S; Ishibashi A; Kani K; Yakabi K
    Digestion; 2018; 97(1):59-63. PubMed ID: 29393142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Yamamoto T; Shimoyama T; Matsumoto K
    Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation and
    Kaidierya A; Zhang RG; Qian HN; Zou ZY; Danniya Y; Fan TY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1202-1207. PubMed ID: 36533356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.
    Ding H; Liu XC; Mei Q; Xu JM; Hu XY; Hu J
    World J Gastroenterol; 2014 Apr; 20(13):3716-8. PubMed ID: 24707159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis.
    Park M; Lee J; Kang SB; Park Y
    Korean J Gastroenterol; 2019 Apr; 73(4):225-229. PubMed ID: 31030460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial].
    Ngô Y; Gélinet JM; Ivanovic A; Kac J; Schénowitz G; Vilotte J; Rambaud JC
    Gastroenterol Clin Biol; 1992; 16(10):782-6. PubMed ID: 1478406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets.
    Goyanes A; Buanz AB; Hatton GB; Gaisford S; Basit AW
    Eur J Pharm Biopharm; 2015 Jan; 89():157-62. PubMed ID: 25497178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients.
    Aumais G; Lefebvre M; Tremblay C; Bitton A; Martin F; Giard A; Madi M; Spénard J
    Aliment Pharmacol Ther; 2003 Jan; 17(1):93-7. PubMed ID: 12492737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the real-life maintenance mesalazine dose in ulcerative colitis?
    Algaba A; Guerra I; García García de Paredes A; Hernández Tejero M; Ferre C; Bonillo D; Aguilera L; López-Sanromán A; Bermejo F
    Rev Esp Enferm Dig; 2017 Feb; 109(2):114-121. PubMed ID: 28026200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
    Kruis W; Neshta V; Pesegova M; Alekseeva O; Andreev P; Datsenko O; Levchenko O; Abdulkhakov S; Lozynskyy Y; Mostovoy Y; Soloviev K; Dorofeyev AE; Vieth M; Stiess M; Greinwald R; Mohrbacher R; Siegmund B
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):98-106.e4. PubMed ID: 29702300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D printed tacrolimus suppositories for the treatment of ulcerative colitis.
    Seoane-Viaño I; Ong JJ; Luzardo-Álvarez A; González-Barcia M; Basit AW; Otero-Espinar FJ; Goyanes A
    Asian J Pharm Sci; 2021 Jan; 16(1):110-119. PubMed ID: 33613734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesalazine-probiotics beads for acetic acid experimental colitis: formulation and characterization of a promising new therapeutic strategy for ulcerative colitis.
    Vishwakarma N; Ganeshpurkar A; Pandey V; Dubey N; Bansal D
    Drug Deliv; 2015 Jan; 22(1):94-9. PubMed ID: 24491122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.
    Marteau P; Crand J; Foucault M; Rambaud JC
    Gut; 1998 Feb; 42(2):195-9. PubMed ID: 9536943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions.
    Jacobsen BA; Abildgaard K; Rasmussen HH; Christensen LA; Fallingborg J; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1991 Apr; 26(4):374-8. PubMed ID: 2034991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
    Andus T; Kocjan A; Müser M; Baranovsky A; Mikhailova TL; Zvyagintseva TD; Dorofeyev AE; Lozynskyy YS; Cascorbi I; Stolte M; Vieth M; Dilger K; Mohrbacher R; Greinwald R;
    Inflamm Bowel Dis; 2010 Nov; 16(11):1947-56. PubMed ID: 20310020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.